663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC

• DOI: 10.1016/j.annonc.2023.09.1849
• Publication Date: 2023-10-20T12:30:24Z
• Authors: C. Rojas; I. Lugowska; R. Juergens; A. Sacher; S. Weindler; M.A.N. Sendur; R. Dziadziuszko; A. Pal; E. Castanon Alvarez; E.S. Ahern; N. Lakhani; L-C. Chen; T. Jemielita; Y.S. Choi; A. Stathis
• Keywords: Clinical endpoint